Friday January 30, 1:43 pm Eastern Time
Company Press Release
Harvard Scientific Receives Notification of Patent No.
5,718,917 From U.S. Patent and Trademark Office
RENO, Nev.--(BW HealthWire)--Jan. 30, 1998--Harvard Scientific Corp. (OTC BB:HVSF - news), a
Nevada corporation, announced Friday that it has been notified by the U.S. Patent and Trademark
Office that it will issue patent no. 5,718,917 entitled ''PGE-1 CONTAINING LYOPHILIZED
LIPOSOMES FOR USE IN THE TREATMENT OF ERECTILE DYSFUNCTION'' to the company. The notification
stated the anticipated date of issuance to be Feb. 17, 1998. The company filed patent
application no. 08/573,408 on Dec. 15, 1995, and received Notice of Allowance for its
application from the U.S. Patent and Trademark Office on Aug. 18, 1997.
Company President and CEO, Thomas Waite stated: ''Today, a great milestone has been achieved
and the company is obviously very pleased to receive this notification which identifies the
patent number for its male erectile dysfunction treatment product. Dr. Jackie See, director of
Research and Development and the coordinated efforts of all the company's team of experts
assembled thus far which include Dr. Darryl See, project manager, Dr. Lorenz Hofmann,
consultant for Clinical Operations and Regulatory Affairs, and Dr. Irwin Goldstein, medical
consultant for IND Clinical Trials and a Clinical Trial Investigator have done a tremendous job
and deserve a great deal of the credit for the company's success to date.''
Harvard Scientific Corp. is a biopharmaceutical company that develops products relating to
liposomal delivery of Prostaglandin E-1 for the treatment of male erectile dysfunction,
impotency and sexual enhancement. The company's patented process allows the Prostaglandin E-1
to be administered as a liquid via a painless delivery system. The company also has developed a
topically applied skin treatment for psoriasis and is working with the FDA to establish Phase I
clinical trials protocol for that product.
Prostaglandin E-1 is a naturally occurring vasodilator originally approved by the U.S. FDA for
intravenous infusion in neonates. In 1995, PGE-1 was approved by the FDA as a treatment for
male erectile dysfunction for Upjohn's Caverject(r), which is administered by needle injection.
In November 1996, Vivus Inc [Nasdaq:VVUS - news].'s MUSE(r) delivery system was approved by the
FDA. The company believes that its product represents a tremendous treatment advantage over
other delivery systems currently being utilized in the industry.
From time to time the company may issue forward looking statements which involve risks and
uncertainties. This statement may contain forward looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Actual results could differ and any forward looking
statements should be considered accordingly.
Contact:
I.W. Miller & Co.
Ira Miller, 714/833-9001
or
Martin E. Janis & Co.
Hal Schweig, 312/943-1100
or
Harvard Scientific Corp.
Michael Snell, 407/324-1606 |
